Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeks/months. Ability to expand ARCT-154 in the Covid-19 booster treatment market space; Company already received feedback from several regulators for such a pivotal booster study for Covid-19.

Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space

Shares of Acturus Therapeutics Holdings Inc. ARCT, -1.43% were down 2.3% in trading on Wednesday after the company said two doses of its experimental COVID-19 vaccine had an efficacy rate of 55% against infection. The Phase 3 clinical trial evaluated the vaccine in 19,000 people in Vietnam; it also found that the investigational shot had an efficacy rate of 95% against severe disease.

Raymond James analyst doesn't expect Arcturus' COVID-19 vaccine to be authorized in the U.S.

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare.

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.  According to analyst Yasmeen.

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

It's not likely, but it could still end up being a good investment.

Could Arcturus Therapeutics Be the Next Moderna?

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2021 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Reports Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Trial

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern. Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty immunization, demonstrated robust antibody responses.

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

The biotech stock climbed more than $5 a share in early trading Thursday.

Why Arcturus Therapeutics Stock Was Up 16% Thursday

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying mRNA vaccine candidates for COVID-19. ARCT-154 and ARCT-165 are being studied in a Phase 1/2 trial in U.S. and Singapore.

Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A.

Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock?

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Arcturus Therapeutics Stock (ARCT)